SAN DIEGO–(BUSINESS WIRE)–Boundless Bio, a company interrogating and targeting ecDNA in aggressive cancers, announced the completion of a $46.4M Series A financing.
Boundless Bio Launches to Deliver Transformative Therapies to Patients with Difficult-to-Treat Cancers Driven by Extrachromosomal DNA
